INGN: here's a good one...
Introgen: Dawson James believes yesterday's recommendation of DNDN's Provenge a major plus for INGN's Advexin (3.88 )
Boutique firm Dawson James says yesterday the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 13-4 to recommend DNDN's Provenge immunoterhapry for prostate cancer with very limited data (only 82 treated patients with just 21% increase in survival). Firm believes this is a major plus for INGN as the CTGTAC is the same panel that will review Advexin. They continue to believe this indicates a new, more lenient advisory panel stance with respect to biological therapies with few side-effects under new FDA Commissioner Andrew von Eschenbach. Firm believes that INGN's Advexin data set is at least as comparable especially when using biomarker data.
"Illegitimacy is something we should talk about in terms of not having it."
- Dan Quayle
